Otros idiomas Sagimet Biosciences Inc.

Acciones

SGMT

US7867001049

Precio de cierre Nasdaq Otros sitios de cotización 00:00:00 08/05/2024			Varia. Cinco días.	Varia. 1 de enero.
4,44 ^USD	+2,54 %		+8,03 %	-18,08 %

06/05	Sagimet Biosciences nombra a Thierry Chauche director financiero	MT
02/05	SAGIMET BIOSCIENCES INC. : HC Wainwright mantiene su recomendación de compra	ZM

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024	07/05
Sagimet Biosciences Names Thierry Chauche CFO	06/05
Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer	06/05
Sagimet Biosciences Inc. Announces Appointment of Thierry Chauche as Chief Financial Officer	06/05
Certain Warrants of Sagimet Biosciences Inc. are subject to a Lock-Up Agreement Ending on 25-APR-2024.	25/04
Certain Options of Sagimet Biosciences Inc. are subject to a Lock-Up Agreement Ending on 25-APR-2024.	25/04
Certain Series A Common Stock of Sagimet Biosciences Inc. are subject to a Lock-Up Agreement Ending on 25-APR-2024.	25/04
Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024	22/04
Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat	27/03
Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat	27/03
Sagimet Biosciences Inc. Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat	27/03
Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors	25/03
Sagimet Biosciences Inc. Announces Management Changes	25/03
Sagimet Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	25/03
Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates	25/03
Sagimet Biosciences to Participate in Two Upcoming Investor Conferences	29/02
Sagimet Biosciences to Participate in Two Upcoming Investor Conferences	29/02
Top Premarket Decliners	26/01
Sagimet Biosciences Prices $112.5 Million Common Stock Offering; Shares Fall Pre-Bell	26/01
Sagimet Biosciences Announces Pricing of Public Offering of Series A Common Stock	26/01

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Sagimet Biosciences Inc.

Acciones

SGMT

US7867001049

Otros idiomas

Filtros